Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Colorectal Cancer: KOL Insight 2016

Product Code:
596200707
Publication Date:
October 2016
Format:
PDF
Price:
£8,895

KOLs embrace novel MoAs as low survival rates drive search for new treatments

Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). Some say novel therapies are the key. Others argue that a deeper understanding of the disease may have more of an impact by enabling personalised treatments.

Find out how the treatment algorithm is likely to evolve over the next five years in KOL Insight: Colorectal Cancer.

You’ll get 12 North American and European KOLs’ candid thoughts on 6 recently marketed CRC treatments and 13 more currently in the pipeline.

Discover how PD-1/PD-L1 inhibitors, BRAF/MEK inhibitors, and other new therapies are likely to be used, how they’ll affect current mainstays such as anti-VEGF therapies and EGFR inhibitors, and which new combination therapies show the most promise.

Download sample pages

Plus: Order the report and you’ll receive three quarterly FirstWord Therapy Trends Update Bulletins free!

See the Top Takeaways >

 “I think the lesson we have learnt in colon cancer is that if we want to push the survival number up and up and up, we have to think of ways of combining different strategies.”
US Key Opinion Leader

Sample of brands covered:

  • Avastin (bevacizumab; Roche/Chugai)
  • Keytruda (pembrolizumab; Merck & Co.)
  • Tecentriq (atezolizumab; Roche)
  • Encorafenib and Binimetinib (Array BioPharma)
  • Cobimetinib (Cotellic; Exelixis/Roche)
  • Plus 13 moredownload the full list now >

Sample of KOLS interviewed

  • Dr Al B. Benson III. Professor of Medicine, Division of Hematology/Oncology, Northwestern University’s Feinberg School of Medicine, Chicago, Illinois, US.
  • Dr Bassel F. El-Rayes. Director of the GI Oncology Clinical and Translational Research Program, Associate Cancer Research Director for Clinical Research, Winship Cancer Institute of Emory University; John Kauffman Family Professor of Hematology and Oncology, Emory University School of Medicine, Atlanta, Georgia, US.
  • Dr Marwan Fakih. Professor and Section Head Chief for GI Oncology, City of Hope Comprehensive Cancer Center, Los Angeles, California, US.
  • Dr Michael Morse. Professor of Medicine in the Division of Medical Oncology and Professor in the Department of Surgery, Duke University Medical Center, Durham, North Carolina, US.
  • Professor Jaafar Bennouna. Head of Department at ICO Paul Papin et René Gauducheau Hospital, Saint-Herblain, France.
  • Plus 8 moredownload the full list now >
Back to the top

Top Takeaways

  • Unmet need is the #1 concern: Many CRC subtypes have a poor prognosis. Which patient population represents the greatest unmet need? Which new therapies do KOLs expect to help most?
  • Deeper understanding required: Some KOLs believe that better physical and molecular classification of CRC, combined with increased use of biomarkers, may have more of an impact than new medicines.
  • Outlook unclear for anti-VEGFs and EGFR inhibitors: KOLs are split on whether these backbone therapies will see continued widespread use as front-line and later line treatments respectively. What will determine their positions in the treatment algorithm?
  • KOLs enthusiastic about PD-1/PD-L1 inhibitors: Although some note that immunotherapies like Keytruda and Tecentriq are most effective in a small subset of patients. How are they likely to be used?
  • New combinations on the horizon: While chemotherapy-backed combinations are widely used in CRC, some KOLs believe targeted therapy combinations may prove more effective for many patients.
  • Hunger for alternative treatments: KOLs are upbeat about novel mechanisms of action—but not all of them. Which pipeline therapies are they most excited about? Which ones are they most sceptical of?
  • Mixed feelings about biosimilar bevacizumab: With at least six Avastin biosimilars on the way, KOLs are cautiously optimistic. What are their concerns, and what will biosimilars have to show to achieve widespread uptake?
  • Cost concerns are mounting: KOLs anticipate that new CRC treatments will come with a high price tag. How will that affect treatment and regulatory decisions?
Request sample pages

Back to the top

Money Back Guarantee

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

  • Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date.
  • You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.



customer.service@firstwordpharma.com

All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved